Signaturefd LLC Grows Position in Genmab A/S (NASDAQ:GMAB)

Signaturefd LLC boosted its position in shares of Genmab A/S (NASDAQ:GMAB) by 32.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,900 shares of the company’s stock after acquiring an additional 1,920 shares during the period. Signaturefd LLC’s holdings in Genmab A/S were worth $193,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. DDD Partners LLC purchased a new stake in Genmab A/S during the second quarter worth approximately $8,860,000. Capital International Investors raised its holdings in Genmab A/S by 7.8% during the first quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock worth $130,805,000 after purchasing an additional 315,355 shares in the last quarter. Cubist Systematic Strategies LLC lifted its position in shares of Genmab A/S by 109.7% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after buying an additional 145,689 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Genmab A/S by 7.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock valued at $36,752,000 after buying an additional 103,859 shares in the last quarter. Finally, Sanctuary Advisors LLC purchased a new position in shares of Genmab A/S in the 2nd quarter valued at $1,354,000. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Stock Performance

GMAB stock opened at $23.12 on Monday. Genmab A/S has a one year low of $22.39 and a one year high of $32.89. The company has a fifty day moving average of $25.34 and a 200-day moving average of $26.81. The stock has a market capitalization of $15.30 billion, a PE ratio of 19.11, a price-to-earnings-growth ratio of 0.68 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). The business had revenue of $779.50 million during the quarter, compared to analysts’ expectations of $734.60 million. Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. Equities analysts forecast that Genmab A/S will post 1.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GMAB has been the subject of a number of research reports. Morgan Stanley reissued an “equal weight” rating and issued a $31.00 price target on shares of Genmab A/S in a research report on Wednesday, September 11th. Truist Financial decreased their target price on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, September 9th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Wednesday, October 16th. Finally, Redburn Atlantic started coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They issued a “buy” rating for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $45.20.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.